Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H28N2O3.C2H4O2 |
Molecular Weight | 452.5427 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.CCC1=CC2=C(CC(C2)NC[C@H](O)C3=CC=C(O)C4=C3C=CC(=O)N4)C=C1CC
InChI
InChIKey=HZHXFIDENGBQFQ-FTBISJDPSA-N
InChI=1S/C24H28N2O3.C2H4O2/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;1-2(3)4/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1H3,(H,3,4)/t22-;/m0./s1
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16022567
Curator's Comment: # Novartis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514 |
76.0 nM [Ki] | ||
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218 |
91.4 nM [Ki] | ||
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514 |
76.0 nM [Ki] | ||
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20655218 |
91.4 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ARCAPTA NEOHALER Approved UseUTIBRONTM NEOHALER® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important Limitations of Use: UTIBRON NEOHALER is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1, 5.2) Launch Date2011 |
|||
Primary | ARCAPTA Approved UseINDICATIONS AND USAGE. ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important limitations: ARCAPTA NEOHALER is NOT indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ARCAPTA NEOHALER is NOT indicated for asthma. Launch Date2011 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
528 pg/mL |
110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE |
INDACATEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
339 pg/mL |
110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE |
INDACATEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.206 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.518 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.299 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.697 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2750 pg × h/mL |
110 μg 1 times / day steady-state, respiratory dose: 110 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: GLYCOPYRROLATE |
INDACATEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
907 pg × h/mL |
110 μg single, respiratory dose: 110 μg route of administration: Respiratory experiment type: SINGLE co-administered: GLYCOPYRROLATE |
INDACATEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.974 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg single, respiratory dose: 150 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg single, respiratory dose: 300 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.51 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
116 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
150 μg 1 times / day steady-state, respiratory dose: 150 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
118 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24705947/ |
300 μg 1 times / day steady-state, respiratory dose: 300 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
INDACATEROL serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Disc. AE: Dyspnea, Wheezing... AEs leading to discontinuation/dose reduction: Dyspnea (serious, 1 patient) Sources: Wheezing (serious, 1 patient) Asthma (moderate, 1 patient) Cough (moderate, 1 patient) |
75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma Sources: |
Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Asthma | moderate, 1 patient Disc. AE |
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Cough | moderate, 1 patient Disc. AE |
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Dyspnea | serious, 1 patient Disc. AE |
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Wheezing | serious, 1 patient Disc. AE |
800 ug 1 times / day multiple, respiratory Highest studied dose Dose: 800 ug, 1 times / day Route: respiratory Route: multiple Dose: 800 ug, 1 times / day Sources: |
unhealthy, 43.5 years (range: 12.0–64.0 years) n = 59 Health Status: unhealthy Condition: COPD Age Group: 43.5 years (range: 12.0–64.0 years) Sex: M+F Population Size: 59 Sources: |
Adverse event | grade 5 | 75 ug 1 times / day multiple, respiratory Dose: 75 ug, 1 times / day Route: respiratory Route: multiple Dose: 75 ug, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000PharmR.pdf#page=46 Page: 46.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Gateways to clinical trials. | 2006 Jan-Feb |
|
Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. | 2007 Mar |
|
Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study. | 2008 Dec |
|
Gateways to clinical trials. | 2008 Jan-Feb |
|
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. | 2008 Jul |
|
Novel long-acting bronchodilators for COPD and asthma. | 2008 Oct |
|
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. | 2009 Feb |
|
Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist. | 2009 Sep |
|
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. | 2010 Jun |
|
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. | 2010 Mar 8 |
|
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. | 2010 May 13 |
|
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. | 2010 Oct 29 |
|
Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. | 2010 Sep |
|
Metabolism and pharmacokinetics of indacaterol in humans. | 2012 Sep |
|
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study. | 2017 Jan 11 |
Sample Use Guides
The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16022567
In the isolated tracheal strip preparation, indacaterol, demonstrated concentration-dependent inhibition of electrically induced contraction (EC50= 45 ± 13 nM)
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
24178422
Created by
admin on Sat Dec 16 02:18:07 GMT 2023 , Edited by admin on Sat Dec 16 02:18:07 GMT 2023
|
PRIMARY | |||
|
1000160-96-2
Created by
admin on Sat Dec 16 02:18:07 GMT 2023 , Edited by admin on Sat Dec 16 02:18:07 GMT 2023
|
PRIMARY | |||
|
RYI4401DTM
Created by
admin on Sat Dec 16 02:18:07 GMT 2023 , Edited by admin on Sat Dec 16 02:18:07 GMT 2023
|
PRIMARY | |||
|
DTXSID70142865
Created by
admin on Sat Dec 16 02:18:07 GMT 2023 , Edited by admin on Sat Dec 16 02:18:07 GMT 2023
|
PRIMARY | |||
|
100000183717
Created by
admin on Sat Dec 16 02:18:07 GMT 2023 , Edited by admin on Sat Dec 16 02:18:07 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD